NCT03510338View on ClinicalTrials.gov

Pharmacoscintigraphic Study to Evaluate Two Sildenafil Products

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 8, 2018

Primary Completion Date

June 13, 2018

Study Completion Date

June 13, 2018

Conditions
Erectile Dysfunction
Interventions
DRUG

Sublingual sildenafil

100 mg biphasic sildenafil tablet

DRUG

Oral sildenafil

50 mg oral sildenafil (Viagra)

Trial Locations (1)

G4 0SF

BDD Pharma Ltd, Glasgow

Sponsors

Collaborators (1)

BDD Pharma Ltd
All Listed Sponsors
collaborator

BDD Pharma Ltd

INDUSTRY

lead

N4 Pharma UK Ltd.

INDUSTRY

NCT03510338 - Pharmacoscintigraphic Study to Evaluate Two Sildenafil Products | Biotech Hunter | Biotech Hunter